A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
Phase 1
Recruiting
- Conditions
- B-cell Non-Hodgkin LymphomasAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Antengene Biologics Limited
- Target Recruit Count
- 48
- Registration Number
- NCT06028373
- Locations
- ๐บ๐ธ
University of California San Francisco (UCSF), San Francisco, California, United States
๐บ๐ธRegents of the University of Colorado, Aurora, Colorado, United States
๐บ๐ธYale University, New Haven, Connecticut, United States
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Antengene Biologics Limited
- Target Recruit Count
- 156
- Registration Number
- NCT05718895
- Locations
- ๐ฆ๐บ
Integrated Clinical Oncology Network Pty Ltd (Icon), South Brisbane, Australia
๐จ๐ณThe Affiliated Hospital of Qingdao University, Qingdao, China
๐ฆ๐บCancer Research SA Pty Ltd, Adelaide, Australia
A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorMetastatic Solid TumorMature B-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Antengene Biologics Limited
- Target Recruit Count
- 40
- Registration Number
- NCT04986865
- Locations
- ๐บ๐ธ
University of California San Francisco, San Francisco, California, United States
๐บ๐ธWashington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath